Insights Center
Thought leadership, news, events — you will find them all here, right at your fingertips. We’ve consolidated the firm’s most popular content in one, easy to search location. Enter a key word or phrase to find pertinent blog posts, articles, press releases, and upcoming events.
Mintz Viewpoints
Showing 2225 - 2232 of 12086 results

How The America Invents Act Has Hurt SMEs
September 21, 2022| News

From the Edge - In the Boardroom: Session 3 - Board Committees
September 21, 2022| Podcast| Viewpoint

On Sharing and Managing Competitively Sensitive Information in M&A Transactions
September 20, 2022| Advisory| Viewpoint

Pharmaceutical Manufacturer Pays $7.9 Million to Resolve Allegations that it Caused the Submission of Over-the-Counter Drugs to Medicare Part D
September 20, 2022| Blog| Viewpoint

MintzTech Connect Industry News: Spotlight on Adgile Media Group
September 19, 2022| Article| Viewpoint

MintzTech Connect Industry News: Spotlight on Radicle Science
September 19, 2022| Article| Viewpoint

MintzTech Connect: All Things Technology — September 2022
September 19, 2022| Article| Viewpoint

What's At Stake For The Muni Market In Midterm Elections?
September 19, 2022| News
News & Press Releases
Mintz advised the creators of Morbid, one of the top-charting true crime podcasts, in a multi-year agreement to move to SiriusXM from Wondery. The deal gives SiriusXM exclusive advertising rights for the audio and video formats of the podcast.
Mintz Advises CVC DIF in Acquisition of SBA Communications’ Canadian Tower Infrastructure Platform
August 06, 2025
Mintz advised CVC DIF, the dedicated infrastructure investment strategy of global private markets manager CVC, in its agreement to acquire SBA Communications’ Canadian wireless tower business, one of Canada’s leading independent owners and operators of wireless communications towers. The transaction is expected to close in the fourth quarter of 2025, subject to customary closing conditions.
Mintz advised the underwriters in connection with a $69 million public offering by Larimar Therapeutics, Inc. of 21,562,500 shares of its common stock at a price to the public of $3.20 per share. The gross proceeds to Larimar from the offering were $69 million before deducting underwriting discounts and commissions and other offering expenses.
Events
Podcasts

Mintz On Air: Practical Policies — A Private Equity Non-Compete Primer
July 15, 2025| Podcast|

Health Law Diagnosed – Best Practices for Communicating with the FDA
July 9, 2025| Podcast|
